Anti-AA2AR/ ADORA2A/ A2aR monoclonal antibody
Anti-AA2AR/ ADORA2A/ A2aR antibody for FACS & in-vivo assay
Go to ADORA2A/ADORA2A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T77365-Ab-1/ GM-Tg-hg-T77365-Ab-2 | Anti-Human ADORA2A monoclonal antibody | Human |
GM-Tg-rg-T77365-Ab-1/ GM-Tg-rg-T77365-Ab-2 | Anti-Rat ADORA2A monoclonal antibody | Rat |
GM-Tg-mg-T77365-Ab-1/ GM-Tg-mg-T77365-Ab-2 | Anti-Mouse ADORA2A monoclonal antibody | Mouse |
GM-Tg-cynog-T77365-Ab-1/ GM-Tg-cynog-T77365-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ADORA2A monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T77365-Ab-1/ GM-Tg-felg-T77365-Ab-2 | Anti-Feline ADORA2A monoclonal antibody | Feline |
GM-Tg-cang-T77365-Ab-1/ GM-Tg-cang-T77365-Ab-2 | Anti-Canine ADORA2A monoclonal antibody | Canine |
GM-Tg-bovg-T77365-Ab-1/ GM-Tg-bovg-T77365-Ab-2 | Anti-Bovine ADORA2A monoclonal antibody | Bovine |
GM-Tg-equg-T77365-Ab-1/ GM-Tg-equg-T77365-Ab-2 | Anti-Equine ADORA2A monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T77365-Ab-1/ GM-Tg-hg-T77365-Ab-2; GM-Tg-rg-T77365-Ab-1/ GM-Tg-rg-T77365-Ab-2; GM-Tg-mg-T77365-Ab-1/ GM-Tg-mg-T77365-Ab-2; GM-Tg-cynog-T77365-Ab-1/ GM-Tg-cynog-T77365-Ab-2; GM-Tg-felg-T77365-Ab-1/ GM-Tg-felg-T77365-Ab-2; GM-Tg-cang-T77365-Ab-1/ GM-Tg-cang-T77365-Ab-2; GM-Tg-bovg-T77365-Ab-1/ GM-Tg-bovg-T77365-Ab-2; GM-Tg-equg-T77365-Ab-1/ GM-Tg-equg-T77365-Ab-2 |
Products Name | Anti-ADORA2A monoclonal antibody |
Format | mab |
Target Name | ADORA2A |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-ADORA2A benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species AA2AR/ ADORA2A/ A2aR VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | vGMAAV000023 | human ADORA2A AAV particle |
ORF Viral Vector | pGMAAV000023 | human ADORA2A AAV plasmid |
ORF Viral Vector | vGMAP000328 | Human ADORA2A Adenovirus particle |
ORF Viral Vector | pGMAP000328 | Human ADORA2A Adenovirus plasmid |
ORF Viral Vector | vGMAAV000313 | human ADORA2A AAV particle |
ORF Viral Vector | pGMAAV000313 | human ADORA2A AAV plasmid |
ORF Viral Vector | pGMLPm002849 | mouse Adora2a Lentivirus plasmid |
ORF Viral Vector | vGMLPm002849 | mouse Adora2a Lentivirus particle |
Target information
Target ID | GM-T77365 |
Target Name | ADORA2A |
Gene ID | 135,11540,25369,707865,403960,101080742,617828,100034039 |
Gene Symbol and Synonyms | A2AAR,A2aR,AA2AR,ADENO,ADORA2,ADORA2A,Adora2l1,ARA2A,RDC8 |
Uniprot Accession | P29274,P30543,P11617,Q6TLI7 |
Uniprot Entry Name | AA2AR_HUMAN,AA2AR_RAT,AA2AR_CANLF,AA2AR_HORSE |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target |
Disease | N/A |
Gene Ensembl | ENSG00000128271 |
Target Classification | Checkpoint-Immuno Oncology |
The target: ADORA2A, gene name: ADORA2A, also named as A2aR, ADORA2, RDC8. This gene encodes a member of the guanine nucleotide-binding protein (G protein)-coupled receptor (GPCR) superfamily, which is subdivided into classes and subtypes. The receptors are seven-pass transmembrane proteins that respond to extracellular cues and activate intracellular signal transduction pathways. This protein, an adenosine receptor of A2A subtype, uses adenosine as the preferred endogenous agonist and preferentially interacts with the G(s) and G(olf) family of G proteins to increase intracellular cAMP levels. It plays an important role in many biological functions, such as cardiac rhythm and circulation, cerebral and renal blood flow, immune function, pain regulation, and sleep. It has been implicated in pathophysiological conditions such as inflammatory diseases and neurodegenerative disorders. Alternative splicing results in multiple transcript variants. A read-through transcript composed of the upstream SPECC1L (sperm antigen with calponin homology and coiled-coil domains 1-like) and ADORA2A (adenosine A2a receptor) gene sequence has been identified, but it is thought to be non-coding. [provided by RefSeq, Jun 2013].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.